Zymeworks Inc. At the core of their mission is the desire to make a meaningful difference for individuals worldwide who are affected by these challenging conditions. With their complementary therapeutic platforms and fully integrated drug development engine, Zymeworks has the flexibility and compatibility to engineer and develop highly differentiated antibody-based therapeutics.

Their extensive experience and capabilities in both antibody-drug conjugates and multispecific antibodies have enabled them to advance a robust pipeline of product candidates. One of their notable achievements is the development of zanidatamab, a HER2-targeted bispecific antibody created using Zymeworks' proprietary Azymetric™ technology. Zymeworks has also partnered with global biopharmaceutical companies, such as BeiGene and Jazz Pharmaceuticals, to further leverage and validate their therapeutic platforms.

In addition to zanidatamab, Zymeworks' next clinical candidate is zanidatamab zovodotin, a HER2-targeted bispecific antibody drug conjugate. This candidate is currently undergoing Phase 1 clinical trials to explore its potential as a treatment for various HER2-expressing cancers. With an accomplished leadership team led by Chair and CEO Kenneth Galbraith and Chief Scientific Officer Paul Moore, Zymeworks is committed to advancing the field of biotechnology and improving patient outcomes